In 2012, the U.S. Food and Drug Administration (“FDA”) approved the above-named Xeljanz medicine in 2012 to treat moderately to severely active rheumatoid arthritis. It later approved the drug for ulcerative colitis, juvenile arthritis, and psoriatic arthritis.
In February 2019, the FDA released a safety alert about an increased risk of blood clots and death. Pfizer has since added a black box warning about these risks.
The FDA has alerted the public that preliminary results from a recent safety clinical trial showed an increased risk in Xeljanz patients for the following medical conditions:
- Heart issues (e.g. heart attack, acute coronary syndrome, aortic dissection)
- Stroke
- Cancer
- Blood Clots
- Arterial or Deep Vein Thrombosis
- Pulmonary Embolism
- Death
If you or a loved one is currently taking Xeljanz or Xeljanz XR, we recommend contacting your prescribing physician to discuss any increased risks of heart-related problems, cancer, and/or blood clots. We also recommend contacting an attorney to protect your legal rights.
Unlike many firms who make big promises and then refer their cases to other attorneys, Meshbesher & Spence will handle your Xeljanz case from beginning to end.
If you have suffered injuries as a result Xeljanz contact Meshbesher & Spence today. Your consultation is free and you pay nothing until our firm recovers fair compensation for you and your family.
